|
Clinical
|
|
Age (years)
|
57 ± 12
|
|
Male gender
|
87% (165)
|
|
Body surface area
|
2.0 ± 0.2
|
|
Coronary Artery Disease Risk Factors
| |
|
Hypertension
|
47% (90)
|
|
Hypercholesterolemia
|
54% (102)
|
|
Diabetes mellitus
|
28% (53)
|
|
Tobacco use
|
35% (66)
|
|
Family history
|
30% (56)
|
|
Cardiovascular Medications
| |
|
Beta-blocker
|
91% (173)
|
|
ACEI/ARB
|
60% (113)
|
|
Loop diuretic
|
15% (28)
|
|
Statin
|
93% (177)
|
|
Aspirin
|
98% (186)
|
|
Thienopyridine
|
83% (158)
|
|
Warfarin
|
5% (9)
|
|
Nitroglycerin
|
13% (25)
|
|
Cardiac morphology/function
|
|
Left Ventricle
|
|
Ejection fraction (%)
|
52.2 ± 13.3
|
|
LV dysfunction (EF < = 55%)
|
55% (105)
|
|
End-diastolic volume (ml)
|
161.9 ± 49.2
|
|
End-systolic volume (ml)
|
81.6 ± 46.4
|
|
Myocardial mass (g)
|
137.9 ± 38.2
|
|
Late gadolinium enhancement (present)
|
98% (186)
|
|
Infarct size (% myocardium)
|
14.5 ± 10.4
|
|
Aortic Valve
|
|
Bileaflet
|
2% (3)
|
|
Thickening/ fibrocalcific changes
|
12% (23)
|
|
Stenosis
|
2% (4)
|
|
Regurgitation
|
7% (13)
|
